Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274508 · ClinicalTrials.gov registry record · Phase 3
Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 261
- Enrollment target
NCT00274508: Completed Phase 3 study, sponsored by Boehringer Ingelheim.
NCT00274508 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 261 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00274508, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 261 participants
- Enrollment target
Study Summary
To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD
Interventions
- DRUG tiotropium bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2000-10-10 |
| Phase | Phase 3 |
What the finished NCT00274508 record still lists
NCT00274508 is an interventional study that assigns participants to a tested intervention. The registered 261 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 1 intervention - of which tiotropium bromide is the first listed.
NCT00274508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00274508 about?
NCT00274508 is a clinical study titled "Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients". To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD
What is the current status of trial NCT00274508?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 261 participants. The study started on 2000-10-10.
What interventions are being tested in trial NCT00274508?
The interventions under investigation include: tiotropium bromide (DRUG).
Who is sponsoring clinical trial NCT00274508?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00274508's enrollment target sits among peer trials
261 1228th of 2000 higher than 771 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05124912 · 261 participants · NA
REMASTer: REcurrent Brain Metastases After SRS Trial
- NCT06559891 · 261 participants · NA
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI